These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23151995)

  • 1. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
    Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
    Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.
    Fontana R; Bregni M; Cipponi A; Raccosta L; Rainelli C; Maggioni D; Lunghi F; Ciceri F; Mukenge S; Doglioni C; Colau D; Coulie PG; Bordignon C; Traversari C; Russo V
    Blood; 2009 Feb; 113(8):1651-60. PubMed ID: 19074732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
    Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
    J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
    Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
    J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically modified T lymphocytes: more than just direct effectors.
    Lamers CH; Debets R
    Immunotherapy; 2013 Jul; 5(7):691-4. PubMed ID: 23829619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAGE A3 antigen-specific cancer immunotherapeutic.
    Peled N; Oton AB; Hirsch FR; Bunn P
    Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
    Bettinotti MP; Panelli MC; Ruppe E; Mocellin S; Phan GQ; White DE; Marincola FM
    Int J Cancer; 2003 Jun; 105(2):210-6. PubMed ID: 12673681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
    Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
    J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
    Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
    Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
    François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
    Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
    Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
    J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
    Saito T; Wada H; Yamasaki M; Miyata H; Nishikawa H; Sato E; Kageyama S; Shiku H; Mori M; Doki Y
    Vaccine; 2014 Oct; 32(45):5901-7. PubMed ID: 25218300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.